MC
MCRB
Seres Therapeutics, Inc.
$5.70
-9.81%
$55.2M
No data for this timeframe.
Vol
Market Cap$55.2M
Cap SizeMicro Cap
Inst. Holders20 funds
Inst. Value$8.8M
Inst. Activity3 buys / 1 sells
Insider Activity0B / 4S
Insider Net $-$3.6K
SEC Reports5
Press Releases3
Recent Activity
Jun 5, 2026
SEC
Seres Therapeutics announced two balance-sheet-strengthening transactions: a $25M buyout of contingent VOWST milestones
8-K — Impact 6/10
Jun 5, 2026
Press
Seres Therapeutics announced a $25M buyout of future VOWST milestones from Nestlé Health Science and a lease restructuri
Impact 5/10
Jun 5, 2026
contract
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
<p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in
May 19, 2026
SEC
Four corporate officers and one director sold a total of 474 shares for ~$3,569 in open-market transactions on May 18, 2
CLUSTER — Impact 2/10
May 18, 2026
Insider
DesRosier Thomas sold 79 shares
See Remarks @ $7.53 ($594.87)
May 18, 2026
Insider
Shaff Eric D. sold 259 shares
Director @ $7.53 ($2.0K)
May 18, 2026
Insider
Henn Matthew R sold 77 shares
See Remarks @ $7.53 ($579.81)
May 5, 2026
SEC
Seres Therapeutics reported Q1 2026 net loss of $19.9M vs net income of $32.7M in Q1 2025 (which included a $50M Nestlé
PRESS-RELEASE — Impact 7/10
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$22.00 (Mar 2026)
Current $5.70
Low $22.00
Median $22.00
High $22.00
1 analysts
$22.00
$22.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.30 ▼ -9.0% | $-2.30 — $-2.30 | -1% YoY | 1 |
| Next Q | $-2.37 ▼ -9.2% | $-2.37 — $-2.37 | -352% YoY | 1 |
| Current FY | $-9.19 ▼ -11.7% | $-9.19 — $-9.19 | -1536% YoY | 1 |
| Next FY | $-10.28 ▼ -12.1% | $-10.28 — $-10.28 | -12% YoY | 1 |
Latest Reports
MIXED
8-K
6/10
Seres Therapeutics announced two balance-sheet-strengthening transactions: a $25M buyout of contingent VOWST milestones
Jun 5, 2026
NEUTRAL
Press
5/10
Seres Therapeutics announced a $25M buyout of future VOWST milestones from Nestlé Health Science and a lease restructuri
Jun 5, 2026
NEUTRAL
CLUSTER
2/10
Four corporate officers and one director sold a total of 474 shares for ~$3,569 in open-market transactions on May 18, 2
May 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $2.6M | — |
| MARSHALL WACE, LLP | $1.2M | ADD |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $934.4K | — |
| BlackRock, Inc. | $905.0K | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $575.7K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | DesRosier Thomas | SELL | $594.87 |
| May 18, 2026 | Shaff Eric | SELL | $2.0K |
| May 18, 2026 | Henn Matthew | SELL | $579.81 |
| May 18, 2026 | Brady Kelly | SELL | $444.27 |
| May 15, 2026 | Brady Kelly | M | $0.00 |
20 institutional holders with $8.8M total value (993,541 shares) as of 2026-Q1. Top holders: VANGUARD, MARSHALL, SUSQUEHANNA.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 294,143 | $2.6M | 29.6% | — |
| 2 | MARSHALL WACE, LLP | 139,539 | $1.2M | 14.0% | ADD +37.4% |
| 3 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 105,339 | $934.4K | 10.6% | — |
| 4 | BlackRock, Inc. | 102,026 | $905.0K | 10.3% | — |
| 5 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 64,900 | $575.7K | 6.5% | — |
| 6 | CITADEL ADVISORS LLC | 59,500 | $527.8K | 6.0% | — |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 56,700 | $502.9K | 5.7% | — |
| 8 | VANGUARD FIDUCIARY TRUST CO | 39,643 | $351.6K | 4.0% | — |
| 9 | STATE STREET CORP | 33,901 | $300.7K | 3.4% | — |
| 10 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 31,630 | $280.6K | 3.2% | — |
| 11 | MORGAN STANLEY | 21,700 | $192.5K | 2.2% | ADD +37.0% |
| 12 | TWO SIGMA INVESTMENTS, LP | 18,794 | $166.7K | 1.9% | — |
| 13 | Invesco Ltd. | 14,547 | $129.0K | 1.5% | ADD +37.5% |
| 14 | BARCLAYS PLC | 6,507 | $57.7K | 0.7% | — |
| 15 | Vanguard Global Advisers, LLC | 1,975 | $17.5K | 0.2% | — |
| 16 | FMR LLC | 1,752 | $15.5K | 0.2% | NEAR_EXIT -99.3% |
| 17 | GROUP ONE TRADING LLC | 824 | $7.3K | 0.1% | — |
| 18 | ROYAL BANK OF CANADA | 107 | $1.0K | 0.0% | — |
| 19 | WELLS FARGO & COMPANY/MN | 10 | $89.00 | 0.0% | DOUBLED +2500.0% |
| 20 | Allworth Financial LP | 4 | $36.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 18,334 | 25,126 | +37.0% | $373.9K | 2025-Q4 |
| Invesco Ltd. | ADD | 10,442 | 14,360 | +37.5% | $213.7K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 10 | 260 | +2500.0% | $3.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 5,343 | 195 | -96.4% | $2.9K | 2025-Q4 |
| MARSHALL WACE, LLP | ADD | 91,405 | 125,600 | +37.4% | $2.4M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 7,838 | 18,334 | +133.9% | $352.7K | 2025-Q3 |
| UBS Group AG | ADD | 7,532 | 12,682 | +68.4% | $244.0K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 186 | 5,343 | +2772.6% | $102.8K | 2025-Q3 |
| FMR LLC | NEAR_EXIT | 268,704 | 1,882 | -99.3% | $36.2K | 2025-Q3 |
6 unique insiders with 17 transactions. Net insider value: -$3.6K ($0.00 bought, $3.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | DesRosier Thomas | See Remarks | SELL | 79 | $7.53 | $594.87 |
| May 18, 2026 | Shaff Eric D. | Director | SELL | 259 | $7.53 | $2.0K |
| May 18, 2026 | Henn Matthew R | See Remarks | SELL | 77 | $7.53 | $579.81 |
| May 18, 2026 | Brady Kelly | See Remarks | SELL | 59 | $7.53 | $444.27 |
| May 15, 2026 | Brady Kelly | See Remarks | EXERCISE | 180 | — | — |
| May 15, 2026 | Shaff Eric D. | Director | EXERCISE | 391 | — | — |
| May 15, 2026 | DesRosier Thomas | See Remarks | EXERCISE | 244 | — | — |
| May 15, 2026 | Brady Kelly | See Remarks | EXERCISE | 89 | — | — |
| May 15, 2026 | Henn Matthew R | See Remarks | EXERCISE | 141 | — | — |
| May 15, 2026 | Shaff Eric D. | Director | EXERCISE | 722 | — | — |
| May 15, 2026 | Henn Matthew R | See Remarks | EXERCISE | 238 | — | — |
| May 15, 2026 | DesRosier Thomas | See Remarks | EXERCISE | 133 | — | — |
| Mar 4, 2026 | Kender Richard N | See Remarks | AWARD | 150,000 | — | — |
| Mar 4, 2026 | Henn Matthew R | See Remarks | AWARD | 75,000 | — | — |
| Mar 4, 2026 | Thorell Marella | See Remarks | AWARD | 22,500 | — | — |
| Mar 4, 2026 | DesRosier Thomas | See Remarks | AWARD | 22,500 | — | — |
| Mar 4, 2026 | Brady Kelly | See Remarks | AWARD | 56,250 | — | — |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 1 mixed, 2 neutral. Avg impact: 5.2/10.
MIXED
8-K
6/10
Seres Therapeutics announced two balance-sheet-strengthening transactions: a $25M buyout of continge
Jun 5, 2026
NEUTRAL
CLUSTER
2/10
Four corporate officers and one director sold a total of 474 shares for ~$3,569 in open-market trans
May 19, 2026
BEARISH
PRESS-RELEASE
7/10
Seres Therapeutics reported Q1 2026 net loss of $19.9M vs net income of $32.7M in Q1 2025 (which inc
May 5, 2026
BEARISH
8-K
7/10
Seres Therapeutics reported Q1 2026 financial results: net loss of $19.9M vs net income of $32.7M in
May 5, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K reports Items 2.0
Mar 12, 2026
NEUTRAL
5/10
Seres Therapeutics announced a $25M buyout of future VOWST milestones from Nestlé Health Science and
Jun 5, 2026
NEUTRAL
3/10
Seres Therapeutics presented preclinical data for SER-603, a next-generation live biotherapeutic for
May 4, 2026
MIXED
6/10
Seres Therapeutics reported a net income of $5.7 million from continuing operations in 2025, a signi
Mar 12, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$22.00 mean target (Mar 2026)
$22.00 Low
$22.00 High
| Metric | Value |
|---|---|
| Current Price | $5.70 |
| Target Low | $22.00 |
| Target Mean | $22.00 |
| Target Median | $22.00 |
| Target High | $22.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-2.30 | $-2.30 | $-2.30 | -1.3% | -9.0% | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-2.37 | $-2.37 | $-2.37 | -352.1% | -9.2% | — | $0.0B | -100.0% | 1 |
| Current FY 2026-12-31 |
$-9.19 | $-9.19 | $-9.19 | -1535.9% | -11.7% | 0↑ 1↓ | $0.0B | -99.9% | 1 |
| Next FY 2027-12-31 |
$-10.28 | $-10.28 | $-10.28 | -11.9% | -12.1% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.300 | |
| 7d ago | $-2.110 | -0.190 |
| 30d ago | $-2.110 | -0.190 |
| 60d ago | $0.000 | -2.300 |
| 90d ago | $0.000 | -2.300 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Feb 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Jan 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
contract
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
<p align="center"><em>Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net s
May 5, 2026
earnings
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
<p align="center"><em>Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the
May 5, 2026
earnings_calendar
MCRB Q1 2026 Earnings Scheduled — 2026-05-05
May 4, 2026
fda
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
<p align="center"><em>Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal in
Apr 20, 2026
other
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
<p align="center"><em>Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-1
Apr 20, 2026
other
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
<p align="center"><em>Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-1
Mar 12, 2026
earnings
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
<p align="center"><em>Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect i
Mar 11, 2026
earnings_calendar
MCRB Q4 2025 Earnings After Market Close — 2026-03-11
Mar 2, 2026
other
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
<p align="center"><em>Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience</em></p>